ⓘ Adenosine diphosphate receptor inhibitor

                                     

ⓘ Adenosine diphosphate receptor inhibitor

Adenosine diphosphate receptor inhibitors are a drug class of antiplatelet agents, used in the treatment of acute coronary syndrome or in preventive treatment for patients who are in risk of thromboembolism, myocardial infarction or a stroke. These drugs antagonize the P2Y 12 platelet receptors and therefore prevent the binding of ADP to the P2Y 12 receptor. This leads to a decrease in aggregation of platelets, prohibiting thrombus formation. The P2Y 12 receptor is a surface bound protein found on blood platelets. They belong to G protein-coupled purinergic receptors and are chemoreceptors for ADP.

The first drug that was introduced in this class was Tiklopidin, but because of the side effects, it is not often used today. Tiklopidin, clopidogrel and prasugrel Efient all thienopyridine, causing irreversible inhibition of P2Y 12 receptor. They all prolekarsto that need to be converted to the active metabolite in Vivo to inhibit P2Y 12 receptor. On the other hand, new drugs like ticagrelor Brilinta® and cangrelor Kengrexal® are not thienopyridine and to reversibly inhibit P2Y 12 that is, they act directly on the receptor without the requirement of activation of the metabolism and display rapid onset and offset of action.

These drugs are often used in combination with aspirin acetylsalicylic acid to enhance the inhibition of platelets, especially in patients with ACS or undergoing percutaneous coronary intervention PCI.